Opens in a new tab or window The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso ... "Despite the extended survival observed in patients with EGFR variations treated with osimertinib ...

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa ...

Rash occurred in 49% of patients in the lung cancer clinical trials ... % of the body (NCI Common Toxicity Criteria Grade 3 or 4), gefitinib should be discontinued for up to 14 days until ...

Gefitinib is supplied in 250 mg tablets; the recommended daily dose being 250 mg once daily, with or without food. The elimination half-life is 48 hours and the mean bioavailability is 60%.

Dr. Nilanju Sarmah, Head R&D and Academics, Metropolis Healthcare Limited Lung cancer is the leading cause of cancer-related ...

Non-communicable diseases, including cancers such as lung, liver, and breast cancer, account for 77% of total deaths in ...

This is particularly evident in non-small cell lung cancer (NSCLC)-linked EGFR variants ... drug resistance by treating MCF10A cells with gefitinib or osimertinib and analyzing the sgRNA libraries ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...

AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...